الفهرس | Only 14 pages are availabe for public view |
Abstract • Serum fetuin-A as a biomarker for early identification of ESRD patients who are at high risk of cardiovascular disease, shows a sustained decrease of which might account for accelerated atherogenesis and increased risk of mortality. • The effectiveness of serum fetuin-A as a predictive biomarker for cardiovascular disease in hemodialysis patients is increased when it is employed in combination with other proven biomarkers, such as hs-CRP and homocysteine. • Further studies are needed to assess the functional activity of fetuin-A and to investigate if other factors, such as changes in residual renal function, acid-base balance, or nutritional changes may cause a decline of fetuin-A levels during hemodialysis. • Future research studies are needed to evaluate the potential clinical utility of fetuin-A as a novel therapeutic agent to prevent ectopic calcification accompanying various diseases. |